Nonclinical Pharmacokinetics and Pharmacodynamics Characterization of Anti-CD79b/CD3 T Cell-Dependent Bispecific Antibody Using a Surrogate Molecule: A Potential Therapeutic Agent for B Cell Malignancies

The T cell-dependent bispecific (TDB) antibody, anti-CD79b/CD3, targets CD79b and CD3 cell-surface receptors expressed on B cells and T cells, respectively. Since the anti-CD79b arm of this TDB binds only to human CD79b, a surrogate TDB that binds to cynomolgus monkey CD79b (cyCD79b) was used for pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Yadav, Rajbharan, Sukumaran, Siddharth, Zabka, Tanja S., Li, Jinze, Oldendorp, Amy, Morrow, Gary, Reyes, Arthur, Cheu, Melissa, Li, Jessica, Wallin, Jeffrey J., Tsai, Siao, Sun, Laura, Wang, Peiyin, Ellerman, Diego, Spiess, Christoph, Polson, Andy, Stefanich, Eric G., Kamath, Amrita V., Ovacik, Meric A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147001/
https://www.ncbi.nlm.nih.gov/pubmed/35631556
http://dx.doi.org/10.3390/pharmaceutics14050970

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9147001/
https://www.ncbi.nlm.nih.gov/pubmed/35631556
http://dx.doi.org/10.3390/pharmaceutics14050970

Ejemplares similares